Stay updated on RGX-111 Gene Therapy in MPS I Clinical Trial
Sign up to get notified when there's something new on the RGX-111 Gene Therapy in MPS I Clinical Trial page.
Latest updates to the RGX-111 Gene Therapy in MPS I Clinical Trial page
- Check6 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a newer version of the page content.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page’s footer revision/version number has been updated from v3.5.2 to v3.5.3, reflecting a site release rather than any change to the study record.SummaryDifference0.1%
- Check34 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%
- Check48 days agoChange DetectedAdded glossary terms: Mucopolysaccharidosis, MPS-I-H/S and Mucopolysaccharidosis type 1, expanding disease terminology related to the study.SummaryDifference0.1%
- Check55 days agoChange Detected- Hurler-Scheie Syndrome was removed from the list of conditions on the study page. This updates the documented scope of conditions associated with the study.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page notes a FDA clinical hold on RGX-111 due to a safety concern and expands the study details with design, enrollment, locations, eligibility criteria, and pharmacodynamic and safety endpoints.SummaryDifference7%
Stay in the know with updates to RGX-111 Gene Therapy in MPS I Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RGX-111 Gene Therapy in MPS I Clinical Trial page.